Premium
Effect of Salba‐Chia ( Salvia Hispanica L), an Ancient Seed, in the Treatment of Overweight and Obese Patients with Type 2 Diabetes: A Double‐blind, Parallel, Randomized Controlled Trial
Author(s) -
Jenkins Alexandra L,
Brissette Christy,
Jovanovski Elena,
AuYeung Fei,
Ho Hoang Vi Thanh,
Zurbau Andreea,
Sievenpiper John,
Vuksan Vladimir
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.126.2
Subject(s) - overweight , medicine , waist , type 2 diabetes , adiponectin , clinical endpoint , obesity , diabetes mellitus , endocrinology , weight loss , randomized controlled trial , insulin resistance
Preliminary studies indicate that consumption of Salba‐chia ( Salvia hispanica L) improves management of type 2 diabetes and acutely suppresses appetite. In this study, we assessed the effect of Salba‐chia on body weight and related cardiovascular disease risk factors in overweight or obese adults with type 2 diabetes over 6 months. Using a double blind, parallel, controlled trial design, 77 overweight or obese patients with type 2 diabetes (HbA1c 6.8–8.5%; BMI 25–40kg/m 2 ) were recruited. Both groups followed a 6‐month calorie‐restricted diet; one group consumed 30g/1000kcal of Salba‐chia, the other 36g/1000kcal oat bran‐based control, per day. Primary endpoint was change in body weight over 6‐months. Secondary endpoints included changes in waist circumference, body fat %, HbA1c, blood pressure, lipids, C‐reactive protein, and obesity‐related gut hormones. Fifty four participants completed the full 6‐month protocol and 58 (31 Control, 27 Salba‐Chia) were included in the final analysis. At 6‐months, participants on Salba‐chia lost significantly more weight than those on oat bran‐based control (1.9±0.5kg and 0.3±0.4kg, respectively; p= 0.020), accompanied by a greater reduction in waist circumference (3.5±0.7cm and 1.1±0.7cm, respectively; p= 0.027). C‐reactive protein was reduced by 1.1±0.5mg/L (39±17%) on Salba‐chia, compared to 0.2±0.4mg/L (7±20%) on control ( P= 0.045) and plasma adiponectin was increased on Salba‐chia by 6.5±0.7% compared to 0.0±0.6% on control ( P= 0.022). There were no significant differences between treatments on blood pressure, lipids and HbA1c, and fat distribution, however, a within intervention reduction of android (3.7±2.8%, P =0.031) and gynoid fat (6.9±3.9%, P =0.047) was observed in the Salba‐chia group, but not in control. The current trial demonstrates the potential of Salba‐chia to promote weight loss, and improve obesity‐related risk factors, while maintaining good glycemic control. The results suggest Salba‐chia may represent a promising supplementation to conventional therapy in the treatment of overweight and obesity in diabetes. Support or Funding Information Canadian Diabetes Association Operating Grant, Salba‐chia was provided by Salba Smart Natural Products, LLC